UK markets closed
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • FTSE 250

    20,372.52
    +123.78 (+0.61%)
     
  • AIM

    968.25
    +10.25 (+1.07%)
     
  • GBP/EUR

    1.1764
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • BTC-GBP

    22,832.07
    -180.51 (-0.78%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • DOW

    33,212.96
    +575.77 (+1.76%)
     
  • CRUDE OIL

    115.07
    +0.98 (+0.86%)
     
  • GOLD FUTURES

    1,850.60
    +3.00 (+0.16%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • HANG SENG

    20,697.36
    +581.16 (+2.89%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • CAC 40

    6,515.75
    +105.17 (+1.64%)
     

Global Biologics Market Research Report 2022: Revised FDA Regulations to Facilitate Biologics Drug Development - Long-term Forecast to 2030

·6-min read
Company Logo
Company Logo

Global Biologics Market

Global Biologics Market
Global Biologics Market

Dublin, April 22, 2022 (GLOBE NEWSWIRE) -- The "Biologics Global Market Opportunities And Strategies To 2030, By Type, Distribution Channel, Route Of Administration, Drug Classification, Mode Of Purchase" report has been added to ResearchAndMarkets.com's offering.

The global biologics market reached a value of nearly $253,414.8 million in 2020, having increased at a compound annual growth rate (CAGR) of 8.7% since 2015. The market is expected to grow from $253,414.8 million in 2020 to $420,551.5 million in 2025 at a rate of 10.7%. The market is then expected to grow at a CAGR of 9.6% from 2025 and reach $664,744.2 million in 2030.

Growth in the historic period resulted from aging population, government initiatives, ability to command high prices, and increased need for immunology. The market was restrained by pricing pressure from regulators, and lack of awareness on biosimilars among primary care physicians and specialists.

Going forward increase in funding, technological advancements, increase in healthcare access, robust research and development activities for development of oral biologics, lean towards pills over injections, and increasing robust pipeline of biologics will drive the growth. Factors that could hinder the growth of the biologics market in the future include high stringency and low turnover for clinical trials, stringent regulations related to biosimilar approvals, prolonged production and approval time, and nomenclature challenges.

The demand for biologics is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. The pharmaceutical companies across the world are investing in research and development of vaccines against COVID-19, is positively affecting the biologics market. Many vaccines by pharmaceutical companies are under clinical trials. Consequently, if any of the vaccine under trial show further promising results against COVID-19, the biologics market will see significant growth.

The biologics market is highly concentrated, with a small number of large players. The top ten competitors in the market made up to 67.4% of the total market in 2019. Companies in the market face completion for new product developments and technological advances. Major players in the market include Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Merck & Co., Inc., Johnson & Johnson, Bristol Myers Squibb Company, GlaxoSmithKline Plc, Amgen Inc., Sanofi S.A., and Eli Lilly and Company.

The top opportunities in the biologics market segmented by type will arise in the monoclonal antibodies segment, which will gain $75,160.9 million of global annual sales by 2025. The top opportunities in the monoclonal antibodies market segmented by type will arise in the anti-cancer mabs segment, which will gain $40,412.7 million of global annual sales by 2025. The top opportunities in the therapeutic proteins market segmented by type will arise in the metabolic disorders therapeutic proteins segment, which will gain $23,961.4 million of global annual sales by 2025.

The top opportunities in the vaccines market segmented by type will arise in the anti-infective vaccines segment, which will gain $13,307.5 million of global annual sales by 2025. The top opportunities in the biologics market segmented by route of administration will arise in the others segment, which will gain $164,888.7 million of global annual sales by 2025. The top opportunities in the biologics market segmented by drug classification will arise in the branded drugs segment, which will gain $130,303.2 million of global annual sales by 2025.

The top opportunities in the biologics market segmented by mode of purchase will arise in the prescription drugs segment, which will gain $129,786.1 million of global annual sales by 2025. The top opportunities in the biologics market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $79,943.8 million of global annual sales by 2025. The biologics market size will gain the most in the USA at $84,453.4 million.

Market-trend-based strategies for the biologics market include leveraging revised and less stringent regulations to develop new and improved biologics, shifting to biologic drug development to capitalize on the growing demand for these drugs, investing in R&D for the development of innovative biologics, and investing in research and development of biologics for the treatment of complex diseases.

Player-adopted strategies in the biologics market include expanding through establishment of manufacturing and R&D facilities, expanding through new biologic launches for specific diseases and sustainable investments, expanding through acquisition of biotechnology companies, and expanding through strategic collaborations & agreements with industry leaders.

To take advantage of the opportunities, the publisher recommends the biologics companies to focus on research & development, use of large molecules, focus on drug development for complex diseases, expand in emerging markets, set up authorized distributors and sales representatives, leverage online pharmacies, targeting local pharmacies to spread awareness, provide competitively priced offerings in low-income countries to reach new users, skimmed pricing for innovative drugs, direct-to-customer (DTC) advertising, participate in trade shows and events, increased requirement of R&D scientists.

Key Topics Covered:

1. Biologics Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Type
6.2.1. Monoclonal Antibodies (MAbS) Segmentation By Type
6.2.2. Therapeutic Proteins Segmentation By Type
6.2.3. Vaccines Segmentation By Type
6.3. Segmentation By Route Of Administration
6.4. Segmentation By Drug Classification
6.5. Segmentation By Mode Of Purchase
6.6. Segmentation By Distribution Channel

7. Biologics Market Characteristics
7.1. Market Definition
7.2. Segmentation By Type
7.2.1. Therapeutic Proteins
7.2.2. Monoclonal Antibodies ((MAbS)
7.2.3. Vaccines
7.3. Market Segmentation By Route Of Administration
7.3.1. Oral
7.3.2. Others (IV and IP)
7.4. Market Segmentation By Drug Classification
7.4.1. Branded Drugs
7.4.2. Generic Drugs
7.5. Market Segmentation By Mode Of Purchase
7.5.1. Prescription Drugs
7.5.2. Over-The-Counter (OTC) Drugs
7.6. Market Segmentation By Distribution Channel
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Online Pharmacies

8. Biologics Market, Supply Chain Analysis
8.1. Raw Material Suppliers
8.2. Research and Development
8.2.1. Clinical Studies
8.2.2. Contract Research Organization (CRO)
8.2.3. Approval
8.3. Biologics Manufacturing
8.3.1. Contract Manufacturing Organization (CMO)
8.4. Distribution
8.4.1. Wholesalers/Distributors
8.4.2. Retailers
8.4.3. End Users

9. Biologics Market Product Analysis - Product Examples

10. Biologics Market Customer Information
10.1. Awareness Of The Patients For Biosimilars And Biologics
10.2. Perception On The Adoption Of Biosimilars
10.3. Patients' Preference For Biosimilar Over Biologics
10.4. Preference For Influenza Vaccines With Fewer Side Effects
10.5. Hesitance Of Patients Towards Immunization Vaccines Due To Its Side Effects
10.6. Patient Preference for Biologic treatments for Psoriasis
10.7. Patients' Preference for Biologics Over Biosimilar

11. Biologics Market Trends And Strategies
11.1. Revised FDA Regulations To Facilitate Biologics Drug Development
11.2. Higher Profit Margins For Biologics
11.3. Shift From Small Molecules To Biologics
11.4. Robust Research & Development
11.5. Demand For Biologics In The Treatment Of Complex Diseases
11.6. Single Use-Technologies For Cost-Effective Production

Companies Mentioned

  • Merck & Co., Inc.

  • AbbVie Inc.

  • F. Hoffmann-La Roche AG

  • Johnson & Johnson

  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/mkv3x8

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting